Study of Treatment Used for Migraine Headaches (MK-0974-076)

Merck Sharp & Dohme LLC216 enrolled

Overview

This study will describe the reasons for triptan utilization patterns (continuation and discontinuation) in triptan-naïve participants and assess the stability of treatment utilization patterns over time according to standard medical guidelines or clinical practice standards of the investigating physician.

After study start, the Protocol was amended to clarifiy that the first triptan prescription must have been received by the participant within a time window of 3 months (± 2 weeks) prior to the participant being identified by the Investigator, and could be enrolled into the study within 6 months of taking the prescribed triptan medication for the first time and that use of a sample triptan would not disqualify a participant as long as the sample was of the same triptan that was eventually prescribed.

Study Type

OBSERVATIONAL

Enrollment

216

Conditions

Migraine

Interventions

Statin TherapyDRUG

Investigator's choice of any statin.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * At least 18 years of age in the United States at the time of consent * Physician-diagnosed migraine with or without aura * At least two and up to a maximum of 8 moderate to severe migraine attacks during the 30 days prior to screening * Initial triptan prescription 3 months (± 2 weeks) prior to being identified as eligible for this study, and triptan-naïve before that initial prescription * Used triptan medication at least once within 6 months prior to the date of informed consent for screening * Internet access and able to complete online surveys via electronic data entry Exclusion criteria: * Treated with triptans prior to this study * In active litigation and compensation issues including disability dispute cases with a Government agency * Participation in a clinical trial within the last 90 days

Outcomes

Primary Outcomes

Number of Participants Using a Triptan for Migraine Attacks

Participants reported information online. For this measure, the number of participants who used at least one dose of any newly prescribed triptan for the first time in response to a migraine attack were counted.

Time frame: Up to 3 months

Number of Participants Continuing Triptan Therapy

Participants reported information online. For this measure, the number of participants who continued to use a triptan after the first migraine attack were counted; switching from one triptan to another was considered continued use.

Time frame: Up to 3 monoths

Main Reason for Stopping Triptan Use

Time frame: Up to 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.